Lv6
2290 积分 2023-12-13 加入
127P Neoadjuvant IBI310 plus sintilimab in locally advanced MSI-H/dMMR colon cancer: Interim results of the phase III neoshot study
1个月前
已关闭
Neoadjuvant treatment of IBI310 plus sintilimab in locally advanced MSI-H/dMMR colon cancer: A randomized phase 1b study
1个月前
已完结
ACG Clinical Guideline: Hepatic Encephalopathy
1个月前
已完结
Resetting autoimmune disease with CAR cell therapies
2个月前
已完结
Harnessing nucleotide metabolism and immunity in cancer: a tumour microenvironment perspective
3个月前
已完结
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
3个月前
已完结
Efficacy of Second-line Lenvatinib for Hepatocellular Carcinoma After Early Progression on Atezolizumab–Bevacizumab
4个月前
已关闭
Lenvatinib as Second-Line Treatment after Atezolizumab plus Bevacizumab for Unresectable Hepatocellular Carcinoma: Clinical Results Show Importance of Hepatic Reserve Function
4个月前
已完结
Correction to Lancet Oncol 2023; 24: 1399–410
4个月前
已完结
Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma
4个月前
已完结
皖公网安备34019202002308
